| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
|
Medicine details |
|
| Medicine name | dapagliflozin (Forxiga®) |
| Formulation | 5 mg, 10 mg film-coated tablet |
| Reference number | 860 |
| Indication | Add-on combination therapy for the treatment of adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd/AstraZeneca UK Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 14/08/2012 |
| NICE guidance | TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |